Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.63M | 10.94M | 11.15M | 11.52M | 12.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.53M | 21.96M | 26.26M | 36.20M | 40.91M |
| Operating Income | -21.53M | -21.96M | -26.26M | -36.20M | -40.91M |
| Income Before Tax | -21.12M | -21.33M | -25.43M | -35.80M | -40.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.12 | -21.33 | -25.43 | -35.80 | -40.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.12M | -21.33M | -25.43M | -35.80M | -40.29M |
| EBIT | -21.53M | -21.96M | -26.26M | -36.20M | -40.91M |
| EBITDA | -21.52M | -21.94M | -26.23M | -36.15M | -40.85M |
| EPS Basic | -17.94 | -28.17 | -47.58 | -91.96 | -133.59 |
| Normalized Basic EPS | -11.21 | -17.61 | -29.74 | -57.47 | -83.50 |
| EPS Diluted | -17.94 | -28.17 | -47.58 | -91.96 | -133.59 |
| Normalized Diluted EPS | -11.21 | -17.61 | -29.74 | -57.47 | -83.50 |
| Average Basic Shares Outstanding | 6.48M | 4.49M | 2.80M | 1.88M | 1.47M |
| Average Diluted Shares Outstanding | 6.48M | 4.49M | 2.80M | 1.88M | 1.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |